Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2012-03-14 Major Shareholding Noti…
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2012
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding for an individual ('Holder: Thomas Olausson') in a company ('Issuer: Vitrolife AB'). It specifies the 'Before the transaction' and 'After the transaction' share quantities, voting rights, and the resulting percentage, explicitly stating the 'Reason for major shareholding notification Buy'. This directly aligns with the definition of a Major Shareholding Notification, which tracks changes in significant ownership levels crossing thresholds.
2012-03-14 English
Earnings Release 2011
Earnings Release Classification · 99% confidence The document is titled "BOKslutskommuniké 2011" (Year-End Report/Statement 2011) and contains detailed financial results for the fourth quarter and the full year ("Helåret"). It includes key performance indicators (KPIs) like revenue, EBIT, net result, cash flow, and balance sheet metrics, comparing 2011 figures against 2010. The text also includes a CEO commentary discussing business performance and outlook. This structure is characteristic of a comprehensive annual financial report, which aligns with the definition of a 10-K (Annual Report), although the specific Swedish title suggests it might be the preliminary release or the official annual report itself. Given the depth of financial detail covering the full year and the explicit mention of year-end figures, it is classified as the Annual Report (10-K) rather than just an Earnings Release (ER) or a short announcement (RPA/RNS). The length (over 53k characters) also supports this classification over a mere announcement. Q4 2011
2012-02-07 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 95% confidence The document is a 'Report on operations 2011' for Vitrolife AB. It provides detailed financial results for the fourth quarter and the full year 2011, including income statements, cash flow analysis, and management commentary on business performance. It contains substantive financial data and analysis, distinguishing it from a mere announcement or certification. As it covers a full fiscal year but is presented as a report on operations rather than a formal 10-K (which is a specific US regulatory filing), it fits the definition of an Interim/Quarterly Report (IR) or a comprehensive annual financial report. Given the structure and content, it is classified as an Interim/Quarterly Report (IR) as it provides the detailed financial breakdown for the period. FY 2011
2012-02-07 English
Conference call Year-end report 2011
Call Transcript Classification · 90% confidence The document is explicitly titled 'Conference call Year-end report 2011' and serves as an 'Invitation to attend Vitrolife's conference call regarding presentation of the Year-end report for 2011.' It provides details on the time, dial-in numbers, and participants for the call where the annual results will be discussed. This content is characteristic of an announcement for an earnings-related conference call, which aligns with the definition of a Call Transcript (CT) if it were the transcript itself, or more accurately, an invitation/announcement leading up to that event. Since the document is an invitation to a conference call where financial results (Year-end report) will be presented, it is best classified as a Call Transcript (CT) announcement, or if we strictly follow the definitions, it is an announcement related to the presentation of results. Given the options, 'CT' (Call Transcript) is the most relevant category for materials directly related to earnings/results conference calls, even if this specific text is the invitation rather than the transcript itself. However, looking closely at the definitions, 'CT' is defined as the 'Full text transcript of company conference calls'. This document is an *invitation* to the call, not the transcript. The document also mentions the 'press release for Vitrolife's Year-end report will be released at 8.30 CET on the same day.' This suggests the primary purpose is to announce the call related to the annual results presentation. Since there isn't a specific code for 'Conference Call Invitation,' and it is closely tied to the earnings event, 'CT' is the closest fit for the *event* being announced, but the 'Menu vs Meal' rule suggests we look for an announcement type. Since it announces the call where the results are discussed, and it is not the full 10-K or ER, 'CT' remains the most contextually appropriate choice among the provided options for an event focused on discussing financial results.
2012-01-31 English
Telefonkonferens avseende bokslutskommuniké 2011
Report Publication Announcement Classification · 98% confidence The document is a press release dated January 31, 2012, announcing a conference call regarding the 'bokslutskommuniké för 2011' (year-end financial report for 2011). It explicitly states that the actual financial report ('bokslutskommuniké') will be published at 08:30 on the day of the call (February 7th) and that presentation material will be available on the website. Since this document is an announcement about the upcoming release of financial results and the associated conference call, and not the full financial report (10-K) or the earnings highlights (ER) itself, it fits best under the category for announcing the publication of reports. Given the short length (under 5,000 characters) and the focus on announcing the release of the financial communication, Report Publication Announcement (RPA) is the most appropriate classification, as per the 'MENU VS MEAL' rule.
2012-01-31 Swedish
Xvivo blir en mer fristående enhet inom Vitrolife
Board/Management Information Classification · 99% confidence The document is explicitly titled "Pressrelease" and announces significant internal structural changes, including the separation of a subsidiary (Xvivo), changes in executive roles (Magnus Nilsson focusing on Xvivo, Thomas Axelsson as interim CEO for the main business), and plans for executive ownership in the subsidiary. This clearly falls under announcements regarding changes in senior management and board structure. This aligns best with the 'Board/Management Information' category (MANG). Although it is a press release, the core content is management change, not a general regulatory filing (RNS) or a report publication announcement (RPA), as it is substantive news about personnel and structure, not just a notification that a report is available. The document length (4800 chars) is substantial enough to contain the core announcement.
2011-11-24 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.